Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA:688621)

Market Cap	6.40B +25.1%
Revenue (ttm)	1.19B +12.4%
Net Income	194.92M +45.2%
EPS	1.76 +46.8%
Shares Out	109.28M
PE Ratio	33.31
Forward PE	n/a
Dividend	0.16 (0.28%)
Ex-Dividend Date	n/a

Volume	1,861,212
Average Volume	2,693,471
Open	58.00
Previous Close	58.33
Day's Range	57.00 - 59.01
52-Week Range	41.91 - 86.50
Beta	0.13
RSI	36.92
Earnings Date	Apr 24, 2026

About SHA:688621

Beijing Sun-Novo Pharmaceutical Research Co., Ltd., a contract research company, engages in the research and development of drugs in China. The company operates external preparation platform that focuses on the research and development of new drugs and generic drugs for skin external preparations; children's clinical data bridging research center; pediatric drug research and development platform; pediatric drug delivery dosage research and development platform; respiratory tract drug delivery and topical preparation platforms; polypeptide and o...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2009
• Employees: 1,359
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688621

Financial Performance

In 2025, SHA:688621's revenue was 1.22 billion, an increase of 13.33% compared to the previous year's 1.08 billion. Earnings were 203.87 million, an increase of 14.91%.